Clinical Trial Update: Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a biomarker-driven targeted therapy for recurrent platinum-resistant epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED